Cipla inches up on getting USFDA's nod for Icatibant Injectable Pre-Filled Syringe

14 Jul 2020 Evaluate

Cipla is currently trading at Rs. 640.00, up by 1.85 points or 0.29% from its previous closing of Rs. 638.15 on the BSE.

The scrip opened at Rs. 640.00 and has touched a high and low of Rs. 642.85 and Rs. 639.00 respectively.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 696.00 on 22-Jun-2020 and a 52 week low of Rs. 356.75 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 648.00 and Rs. 632.60 respectively. The current market cap of the company is Rs. 51452.18 crore.

The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 40.61% and 22.71% respectively.

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (USFDA).

The company’s Icatibant Injectable Pre-Filled Syringe 30mg/3mL is APrated generic version of Shire’s Firazyr. Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. According to IQVIA (IMS Health), Firazyr and its generic equivalents had US sales of approximately $270 million for the 12month period ending May 2020.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1500.10 -10.80 (-0.71%)
01-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.40
Dr. Reddys Lab 1253.60
Cipla 1500.10
Zydus Lifesciences 914.50
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×